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Transcriptomic dataWe explore the utility of p-value weighting for enhancing the power to detect differential metabolites in a
two-sample setting. Related gene expression information is used to assign an a priori importance level to
each metabolite being tested. We map the gene expression to a metabolite through pathways and then gene
expression information is summarized per-pathway using gene set enrichment tests. Through simulation we
explore four styles of enrichment tests and four weight functions to convert the gene information into a
meaningful p-value weight. We implement the p-value weighting on a prostate cancer metabolomic dataset.
Gene expression on matched samples is used to construct the weights. Under certain regulatory conditions,
the use of weighted p-values does not inﬂate the type I error above what we see for the un-weighted tests
except in high correlation situations. The power to detect differential metabolites is notably increased in
situations with disjoint pathways and shows moderate improvement, relative to the proportion of enriched
pathways, when pathway membership overlaps.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
There is currently an explosion of high-throughput technologies
for assessing global snapshots of the molecular behavior of cells.
Assays exist for measuring DNA sequence, copy number, mRNA
transcript levels, protein presence and abundance, as well as
metabolite abundance in biological samples of healthy and diseased
tissues [1,2]. In the cancer setting, assessment of gene expression is a
prominent tool. Gene expressionmicroarrays have been a mainstay in
gene expression for many years and can measure over 40,000 known
and estimated genes and gene elements per array. New sequencing
technologies, which can be used to measure mRNA abundance, are
not limited by an array design and can also measure many thousands
of mRNA elements in a single experiment.
A less commonly used platform has been that for measuring
metabolites [3]. The metabolome is the cellular complement of small
molecules and includes amino acids, fatty acids, simple carbohy-
drates, and exogenous drugs within the cell. Metabolomic proﬁles are
generated by mass spectrometry (MS) proceeded by either gas or
liquid chromatography (GC or LC). Metabolic proﬁling can currently
detect hundreds of metabolites, compared to the tens of thousands of
mRNA species measured.n), sreekuma@bcm.edu
), ghoshd@psu.edu (D. Ghosh).
rights reserved.The motivating example in this paper considers data from a
prostate cancer study in which both gene expression and metabolites
were measured on the same set of subjects [4]. In particular, samples
come from two groups: cancer and benign. The integrations of such
molecular data sources for exploration and discovery is of growing
interest [5–7]. A variety of visualization tools have recently been
introduced that can map metabolite and gene expression information
onto metabolic pathways, such as [8–10]. A few have some analysis
capability such as correlation measures [9] or enrichment analysis [8].
While there have been previous studies in which metabolite and
gene expression data have been simultaneously measured (e.g., see
[11–15]), much of this work has been in model organisms and the
statistical techniques used have been based on clustering and
pathway analysis. By contrast, in this work, our scientiﬁc goal centers
on the identiﬁcation of differential molecules, which represents a
more supervised analysis. Work in this area has been limited, though
sparse regression methods appear to have promise [16,17]
We use pathway based procedures to integrate the information
from the two platforms and we utilize the theory of weighted multiple
testing as developed by Genovese et al. (2006) [18]. We review this
work in Section 1.1. While the theory proposed there is general, it has
not been applied to the particular problem consideredhere inwhich the
two element types do notmap in a one-to-one fashion. In this paper, we
develop practically useful weighting methods for the speciﬁc problem
of integrating gene expression into analysis of metabolite differential
intensity. A key assumption that will be used is that molecules act in
Table 1
Gene classiﬁcation underlying enrichment testing. Genes are classiﬁed by differential
expression as well as by inclusion in the set of interest. Competitive tests consider the
entire table whereas self-contained tests focus on the ﬁrst row.
Differential Not differential Total
In pathway ξk Xk Gk−Xk Gξk
In pathway complement ξkc D−Xk Gξkc−(D−X) Gξkc
Total D G-D G
Table 2
Four gene-set enrichment tests considered. The competitive hypergeometric and
weighted Kolmogorov–Smirnov tests compare the level of differentiation in the set of
interest to all other sets. The self-contained binomial and sum of squared statistics tests
are global tests of differentiation within the set. Thresholding of per-gene tests prior to
enrichment testing is required for the hypergeometric and binomial tests.
Competitive Self-contained
Binary Hypergeometric Binomial
Continuous Weighted Kolmogorov–Smirnov Sum of squared statistics
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be used to deﬁne pathways to construct weights. In Section 2 we
describe the weightingmethods that we explored. Two simulations are
employed to study these weights in Sections 3.1 and 3.2 and we apply
ourﬁndings to themotivating data example in Section 3.3.We conclude
in Section 4 with some discussion and recommendations.
1.1. Weighted multiple testing and applications to genomic analysis
Consider a set ofm tests in which a positive constant weight, wi, is
applied to each p-value, Pi, for test i=1,…,m, according to its
perceived importance. Holm showed that the sequentially rejective
Bonferroni test (a.k.a. Holm's Test [22]) could be generalized to use
the new p-value, Pi*=Pi/wi, to assess signiﬁcance. Speciﬁcally, if the
ordered weighted p-values are written as P(1)* ≤⋯≤P(m)* then we
reject H0(i) when P(j)* ≤α/(∑k= jm w(k)), j=1,…, i where H0(i) and w(i)
are the hypothesis and weight associated with weighted p-value P(i)* .
This weighted test is designed to control the family-wise error rate
(FWER), i.e. the probability that at least one null hypothesis is falsely
rejected, and does not require that the multiple tests be independent.
Holm's only requirement is that wi≥0.
More recently Genovese, Roeder, and Wasserman (2006) [18]
proposed using p-value weighting with application to genomics
studies. Instead of Holm's test, they use the Benjamini–Hochberg
(BHT) step-down test [23] as the basis of their method. With the BHT,
H0(1),…,H0(i) are rejected formaxi=1,…,m{P(i) :P(i)≤αi/m} where H0(i)
is the hypothesis associated with ordered p-value P(i). The BHT
controls the false discovery rate (FDR), i.e. the expected rate of
incorrectly rejected null hypotheses among all rejected null hypoth-
eses. For testing hundreds, or thousands, of hypotheses controlling
the FDR is less conservative than controlling the FWER. Genovese et
al. (2006) [18] also deﬁne a weight wi≥0 for test i resulting in the
weighted p-value, Pi*=Pi/wi. Again there is no requirement on the
independence of the tests. However, they allow that the set of
weights W={w1,…,wm} be random variables and they additionally
require that w ¼ m−1∑mi¼1wi ¼ 1 to maintain control of the FDR.
Then the weighted-BHT rejects the null hypotheses, H(1),…,H(i) for
maxi=1,…,m{P(i)* :P(i)* ≤ iα/m}, where H0(i) is the null hypothesis
associated with ordered weighted p-value P(i)* , while controlling the
FDR at level α.
Roeder et al. (2006) [24] applied the weighted-BHT to large-scale
genomic studies where thousands of tests are performed and
controlling the error rates leads to a loss of power. In the context of
metabolomic proﬁling we have hundreds of tests, not thousands. In
this setting the low power to detect differential metabolites can arise
in part from small sample sizes [4], as well as from increased
variability due to factors such as diet [25,26] and diurnal rhythm [27].
Yet we know that metabolites do not act in isolation within the cell.
Here we use p-value weights to add information about the behavior
of other molecular components such as gene transcripts in an effort to
add power to nominate metabolites of interest. Through simulation
we ﬁnd that the power can be improved without raising the Type I
error rates above the levels seen in unweighted tests, in the absence
of error rate controlling methods such as Holm's Test or the BHT.
2. Methods
We deﬁne genes γg (g=1,…,G) which have been tested for
differential ability, say between cases (ψ=1) and controls (ψ=0),
producing the test statistics TgG (g=1,…,G). Additionally, we deﬁne
pathways ξk(k=1,…,K) and classify each gene by its differential
ability (|TgG| large) and inclusion in the pathway ξk (γg∈ξk) according
to Table 1. In Section 2.1 we describe four pathway enrichment tests
and identify the per-pathway test statistics Sk they deﬁne. In
Sections 2.2.1 and 2.3 we describe simulation models that explorethe utility of these test statistics, Sk, as weights for tests of per-
metabolite differential ability.
2.1. Enrichment test methods
As described in Table 2 we consider tests based on either binary or
continuous differential expression results. Speciﬁcally, binary tests
require that the per-gene tests are thresholded to categorize each
gene as “differential” or “non-differential”. Continuous tests are based
on a continuous measure of the differential expression per gene, such
as the t-statistic from a two-sample test. Additionally we consider
both competitive and self-contained enrichment tests [28]. A
competitive test compares the genes in the set ξk to the genes in ξkc.
The null hypothesis is that ξk contains the same proportion of
differential genes, say πk, as ξkc. A self-contained test considers only
the genes within the set ξk, and ignores the genes in ξkc. The
hypothesis is that there are no more differential genes than expected
where the expected value is determined a priori, i.e. 5% based on an
α=0.05 error rate, or by sample permutation. Competitive tests
allow selection of a “best” set, i.e. one that is enriched above the rest,
but they are limited in that a given set ξk with πk percent differential
genes will receive a different test statistic depending upon the
proportion of differential genes, say πkc, in the set ξkc. Self-contained
tests will always give the same result for the same set of data since
the test of ξk does not depend on ξkc. However, if differential genes are
uniformly distributed across all pathways, that is πk=π for all
pathways k=1,…,K, then all pathways will be called enriched by a
self-contained test if π is great enough.
2.1.1. Directional hypergeometric test
We assume that Table 1 has a hypergeometric distribution. For
Xk, the number of differential genes in the pathway of interest ξk,
let Xk∼Hyper(Gξk,Gξkc,D). Conduct a directional test of enrichment,
Pr(Xk≥xk|Gξk,Gξkc,D). This test differs from the Fisher's exact test in
that it does not consider the depletion of differential genes in a
pathway ξ as an interesting case. The hypergeometric distribution
assumption provides an exact p-value for this test, without
permutation. Because the hypergeometric test uses the genes of
ξkc to deﬁne the null proportion of differential genes, this is a
competitive test. The test statistic of interest is Sk=Xk.
2.1.2. Weighted Kolmogorov–Smirnov test
The Kolmogorov–Smirnov (K–S) test, also a competitive test,
compares the test statistics of genes in pathway ξk to those in ξkc
using a single ranked list. The degree of separation of the genes in ξk
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begin by ranking the vector of t-statistics TG as (T(1)G ,T(2)G ,…,T(G)G ).
Construct a corresponding pathway inclusion indicator vector I að Þ
where I(γ(g))=1 if γ(g)∈ξk and 0 otherwise. The statistic Sk=maxh|
P(ξk,h)−P(ξkc,h)| is then the maximum deviation of the empirical
distributions, where P(ξk,h)=∑g≤h((νgI(γ(g)))/(∑g=1G νgI(γ(g)))),
P(ξkc,h)=∑g≤h(1− I(γ(g)))/(G−Gξk), and νg∈ [0,1] are weight for γg.
The weighted K–S test as proposed by Subramanian et al. (2005)
[29] for pathway enrichment testing uses νg=|corrj(xig,ψi)|, where xig
is the gene expression level for gene g and person i (i=1,…,N
persons) and ψi=1 for cases and 0 for controls. This weight
emphasizes genes that cluster in the tails of the ranked list by giving
them higher weight. In our simulations we deﬁne νk based on a
function of the per-gene test statistic νg=|TgG|/(1+|TgG|). We choose
this weight for convenience in our simulation but it has a monotonic
relationship with the Pearson's correlation coefﬁcient in the Sub-
ramanian νk and thus only the magnitude of the test statistic will be
affected. Signiﬁcance is determined using permutation sampling of
the sample labels ψi to construct the null distribution or, in the
simulation, draws from the null distribution of test statistics.
2.1.3. Binomial test of proportions
Also called Tukey's Higher Criticism [28], the binomial test of
proportions is self-contained such that only genes contained in
pathway ξk are considered for the test of that pathway (i.e. the top
row of Table 1). Speciﬁcally we assume that Xk, the number of
differential genes in the pathway of interest ξk, is distributed
Xk∼Bin(Gξk,α) where α is set a priori. Under H0 we may set α=0.05,
the Type I error rate for each per-gene test.
In the following, signiﬁcance, i.e., large Xk/Gξk, is determined using
permutation sampling of the sample labels, ψi (i=1,…,N persons), to
construct the null distribution or, in the simulation, draws from the
null distribution of test statistics. The test statistic of interest is
Sk=Xk/Gξk for each pathway k.
2.1.4. Sum of squared test statistics
The test statistic from the sum of squared test statistics method is
simply Sk=∑γg∈ ξk(Tg
G)2, that is the sum of the squared per-gene
test statistics in the set ξk [30]. Signiﬁcance is determined using
permutation sampling of the sample labels, ψi (i=1,…,N persons), to
construct the null distribution or, in the simulation, draws from the
null distribution of test statistics. This is a self-contained test since Sk
and its null distribution consider only the genes in ξk.
2.2. Simulations
Two simulation models were used to explore the various weight
functions. The ﬁrst simulation uses simple construction to explore
speciﬁc properties of the data such as correlation, sample size, and
effect size. The second simulation is derived from real data and thus
has a more complex but realistic construction. This allows us to view
the different weight options in a realistic application while retaining
knowledge of the true nature of the data. Interested readers can ﬁnd
the simulation R code in the supplemental materials online.
2.2.1. Simulation model I
Z-scores are simulated from a standard multivariate normal
distribution to represent the per-gene test statistics of differential
expression (i.e. TgG=ZgG) and per-metabolite test statistics of differ-
ential intensity (ZmM). A constant correlation between like elements,
i.e. gene–gene (ρGG) and metabolite–metabolite (ρMM), and a
constant but lesser correlation between gene and metabolite (ρGM)
within a pathway are assumed. For simplicity we assume that
pathways are disjoint, that is no element appears in multiple
pathways and there is no correlation between elements in differentpathways. The case of non-disjoint pathways will be considered in
Simulation II; see Section 2.3.
We model each pathway to have NkG genes and NkM metabolites.
We draw a vector of z-scores ZG; ZM
 
, where ZkG ¼ zG1 ;…; zGNGk
 
and
ZkM ¼ zM1 ;…; zMNMk
 
, from
ZG; ZM
 
k
∼MVN β ;ϕ
 
;Σ
 
:
The variance covariance matrix is deﬁned per pathway as
Σ ¼
1 ρGG … ρGM ρGM
ρGG 1 ρGM
⋮ ⋱ ⋮
ρGM 1 ρMM
ρGM ρGM … ρMM 1
2
66664
3
77775
NGkþNMkð Þ NGkþNMkð Þ
where ρGMbmin(ρGG,ρMM). Under the null model β ;ϕ
 
is a vector of
zeros.
Under the alternative model, z-scores are simulated from a multi-
variate normal distribution with the same variance–covariance matrix,
Σ
 
, as the null model but with shifted means (β1=⋯=βNkG=β>0 and
ϕ1=…=ϕNkM=ϕ>0). Genes and metabolites are drawn from this
alternative model according to a Bernoulli (πk⋅) distribution thereby
assigning some elements to be truly differential. The probability of
differential elements can differ for genes, πkG∈[0,1], and metabolites,
πkM∈[0,1]. We also allow πkG and πkM to differ by pathway (k) thereby
deﬁning some pathways to be enriched. We retain the simulated state of
differential intensity for each metabolite, m∈(m,…,M) in the vector H
where Hm=0 for the null case and Hm=1 for the differential case. P-
values are calculated from the simulated z-scores using the standard
normal distribution, i.e. p=2Pr(|Z|≥zα/2).
We consider a scenario with 50 pathways and allow the following
parameters to vary:
• Alternative means (ϕ, β): (1.5, 2), (2,3)
• Pathway size (NkM, NkG): (3, 20), (5, 40)
• Percentage of enriched pathways: 10%, 20%
• Correlation between like elements (ρMM,ρGG): 0.2, 0.4, 0.6
• Correlation between gene and metabolite (ρGM): 0.0, 0.10, 0.15,
0.25, 0.50 where ρGMbmin(ρGG,ρMM)
To attain the desired level of enrichment, we set (πkM,πkG)=
(0.75,0.50) for enriched pathways and (πkM,πkG)=(0,0) for non-
enriched pathways when (NkM,NkG)=(3,20). For the larger pathways,
(NkM,NkG)=(5,40), we set (πkM,πkG)=(0.50,0.25) for enriched path-
ways and (πkM,πkG)=(0,0) otherwise.
Each of the four enrichment tests described above was applied to
the gene expression z-scores for each of the 50 pathways. For tests
requiring it, the null distribution was simulated by the generation of
1000 null vectors of z-scores (πkG=πkM=0.05 for all k). The
enrichment test statistic (Sk) and p-value (PSk) for each pathway
(k=1,…,50) were retained. Each of four weight functions was then
applied to convert Sk or PSk into a per-pathway weight that increases
with increasing signiﬁcance of the pathway and that is non-negative.
The functions are: (A) ωk=− log10(PSk), (B) ωk=|~Sk|, (C) ωk=
Φ ð~Sk−~μ Þ, and (D) ωk=exp ð~Sk~μ Þ. The standardized test statistic,
~Sk ¼ Sk−E S0ð Þð Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var S0ð Þ
p
, uses the 1000 null vectors to determine the
null mean, E(S0), and null variance, Var(S0). Estimates of the mean and
variancewere determined from the hypergeometric distribution for the
directional hypergeometric test. Here, Φ(⋅) is the cumulative distribu-
tion function (CDF) for the standard normal distribution and we set
~μ ¼ 2 unless otherwise noted.
With four enrichment scores and four weight functions we are
exploring sixteen separate weights for each pathway,ωkj where j=1,
…,20. The pathway level weights can be applied to the simulated
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metabolite m in pathway k and weight option j. The per-metabolite
weights are then wmj=vmj/v⋅ j where v⋅ j=∑m=1M vmj and thus
wj=M−1∑m=1M wmj=1. The per-metabolite p-values are deter-
mined from the z-score vector ZM by comparing the z-scores to a
standard normal distribution, i.e. PmM=2Pr(|ZmM|≥zα/2). The weighted
per-metabolite p-value, PmjM *, is calculated by PmjM *=PmM/wmj. This
results in sixteen weighted p-values for each metabolite, i.e. anM×16
matrix.
To assess the Type I error rate for each method, with respect to
metabolites, we simulated the situation of completely null data by
generating Z-scores under a model where πkG=πkM=0 for all k. We
also simulated a second null setting in which we assume that there
are differentially expressed elements but that they are not associated
with the pathways. Here we set πkG>0 and πkM>0 to be constant non-
zero rates for all pathways, k∈(1,…,K), to generate differential
elements uniformly across all pathways. The second null model helps
us to determine error rates and to assess any power loss from the
marginal weighting of the null pathways. The power, or the
probability of correctly identifying a differential result, is assessed
using the true state of metabolite differential intensity, Hm, as
simulated by the Bernoulli(πkM) draws. We use receiver operating
characteristic (ROC) curves, varying the signiﬁcance threshold for
Pm
M *, and the associated area under the curve (AUC) to compare the
properties of the different methods.
2.3. Simulation model II
The second simulation makes use of the data structure of the
KEGG pathways between genes and metabolites to deﬁne the
pathways [19–21]. This introduces overlapping pathways and
pathways of varying sizes into the simulation. Rather than drawing
the data from a multivariate normal distribution we use bootstrap
resampling of published gene expression data [31] to populate our
vector of per-gene test statistics. We speciﬁcally focus on those
metabolites measured in Sreekumar et al. (2009) [4] and the genes
measured in Varambally et al. (2005) [31]. The gene and metabolite
information for each human pathway map in KEGG was acquired
from KEGG version 50 (April 2009) using perl scripts and the KEGG
API.
These data include 98 KEGG pathways with measurements of both
genes and metabolites; 76 of these pathways have between 10 and
100 genes measured. For the simulation we selected eight of the 76
pathways to be enriched. We then selected 15 (10.2% of 147) of the
metabolites to be differential. These metabolites were selected in
such a way that they are members of between one and ﬁve pathways
with up to two of the pathways being enriched (see Table 3). By
examining metabolites in multiple pathways we can assess the effect
of weight summaries across pathways. By examining metabolites that
are not in enriched pathways we can examine potential power loss
due to down-weighting.
The Varambally gene expression data were analyzed per gene
using a two-sample t-test with pooled variance. All 126 permutations
of the samples were run and the t-test recalculated to form the
permutation null distribution. To prevent overcounting, the t-
statistics were averaged across probes by gene symbol prior to gene
set enrichment testing. The per-gene test statistic data are simulatedTable 3
Fifteen differential metabolites. The metabolites selected to be simulated as differential
are associated with up to ﬁve pathways, of which, up to two pathways are simulated as
enriched.
Metabolite 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Number of Pathways 5 5 5 4 4 3 3 3 2 2 2 1 1 1 1
Number Enriched 2 1 0 1 0 2 1 0 2 1 0 1 1 0 0by randomly sampling the 2375 mapped genes, with replacement,
from the t-statistic matrix (original t-statistic and 126 permutation
statistics). To induce enrichment, the genes in the enriched pathways
were randomly selected according to a Bernoulli (π) distribution from
the subset of genes that were differential (n=177 at α=0.05), where
π∈(0.2,0.5). That is on average 100π% of the genes in an enriched
pathway were selected to be differential with an effect size as seen in
the Varambally data.
The 147 metabolite p-values were drawn from a uniform
distribution on [0,1]. The p-values of those 15 metabolites that were
selected to be differential were chosen from a Beta(3, 37) distribu-
tion. The shape parameters were chosen for a mean of 0.075 and a
relatively narrow variance to provide the marginal p-values of
interest. Speciﬁcally, the probability of selecting a p-value less than
0.05 is approximately 31% whereas the probability of selecting a p-
value greater than 0.2 is less than 1%. All four enrichment tests, as
described in section 2.1, were run on the gene expression data and
each of the four weight functions, as deﬁned in section 2.2.1, was
calculated. To accommodate metabolites, λm, that belongs to multiple
pathways we summarized the ωk values across pathways within
metabolite, that is vmj= f(ωjkI(λm∈ ξk)). We consider both the median
and the 75th percentile as the summary function, f(⋅). The per-
metabolite weights were then calculated by wmj=vmj/v⋅ j, so that
wj=M−1∑m=1M wmj=1. The gene-set enrichment tests, weight
functions, and per-metabolite weights are calculated for each of 1000
generated gene expression datasets and metabolite p-value vectors.3. Results
3.1. Simulation I: disjoint pathways
Z-scores are simulated from a standard multivariate normal
distribution to represent the per-gene test statistics of differential
expression and per-metabolite test statistics of differential intensity.
The percentage of differentially expressed genes (πkG) and differential
metabolites (πkM) is varied per pathway, k=1,…50, to simulate
enrichment. A constant correlation between like elements, i.e. gene–
gene (ρGG) and metabolite–metabolite (ρMM), and a constant but
lesser correlation between gene and metabolite (ρGM) within a
pathway are assumed. For simplicity we assume that pathways are
disjoint, that is no element appears in multiple pathways and there is
no correlation between elements in different pathways. The case of
non-disjoint pathways will be considered in Simulation II, see
Section 3.2.
Each of the four enrichment tests is used to summarize the
simulated differential gene expression scores. The fourweight functions
are then applied to insure that weights are increasing with increasing
pathway signiﬁcance and are non-negative. In Figs. 1–3 these weights
are labeled A–D and color coded such that the unweighted (raw) p-
values are black, and the four weight functions are (A),ωk=− log10(p),
green; (B), ωk ¼ ~S
 , purple; (C), ωk ¼ Φ ~S−~μ
 
, orange; and (D),
ωk ¼ exp ~S~μ
 
, red.
To assess whether Type I error control is preserved, we considered
two null models. The ﬁrst null model selects no genes and no
metabolites to be differential (πkG=πkM=0 for all k) and was
simulated for varying correlations. We ﬁnd that the Type I error is
near the nominal level except for the highest correlation levels (i.e.
ρGM=0.5). The interquartile range of the error terms includes the
nominal 0.05 error rate except for the exponential weight function
(D, red) which is conservative; see Supplemental Figure S1.
Under the second null model we assume that there are differential
metabolites and genes in the dataset but that they are uniformly
distributed across the dataset, that is they are simulated without
pathway enrichment. Again the interquartile range of the error rates
for each method contains the nominal α=0.05 level with some
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Fig. 1. Average ROC curves from Simulation I. Average receiver operating characteristic (ROC) curves depict the sensitivity and speciﬁcity of each test method and weight function to
detect metabolites simulated to be differential. Each weight function is uniquely colored such that the unweighted(raw) p-values are black, and the four weight functions are (A),
ωk=− log10(p), green; (B),ωk ¼ ~S
 , purple; (C),ωk ¼ Φ ~S−~μ
 
, orange; and (D),ωk ¼ exp ~S ~μ
 
, red. The mean area under the curve (AUC) estimate and associated standard error
are provided in the table below each plot.
269L.M. Poisson et al. / Genomics 99 (2012) 265–274inﬂation in the high correlation cases (e.g. ρGG=ρMM=0.6 and
ρMG=0.5).
As expected, there is some power lost when there is no
enrichment of the pathways, i.e. the gene expression data are not
informative by pathway. On average the loss is between 0.5 and 0.15
points on the AUC scale, except for the exponential weight function
where the conservative error rates are reﬂected in poor power; see
Supplemental Figure S2.
When enrichment of differential metabolites and gene expression
is simulated in a subset of the pathways three of the four weight
functions show robust increases in power over the unweighted case
(raw, black); the p-value weight (A, green), the standardized test
statistic (B, purple), and the CDF transformation (C, orange). Average
ROC curves, across the simulation runs, are used to compare the
sensitivity and speciﬁcity of correctly identifying metabolites simu-
lated to be differential. Fig. 1 shows these average receiver operating
characteristic (ROC) curves from 100 simulated datasets where the
alternative means are ϕ;β
 
¼ 2;3ð Þ. This representative plot is of
data with pathway sizes (NkM,NkG)=(3,20), for genes and metabolites
respectively, and correlations ρGG=ρMM=0.20 and ρGM=0.10. Ten
of 50 pathways (20%) are simulated to be enriched with at (πkM,πkG)=
(0.75,0.50) for k∈(1,…,10) and (πkM,πkG)=(0,0) otherwise. Increas-
ing the correlation to ρGG=ρMM=0.6 and ρGM=0.15 provides only a
marginal increase in the AUC the exponential (D, red) weight
function; see Supplemental Figure S3. The other weight functions
appear to have a minimal loss of power, e.g. AUC=0.98 versus
AUC=0.96 for the hypergeometric test p-value weight (A, green) in
this higher correlation model. When we reduce the effect size of thedifferential elements to have alternative means ϕ;β
 
¼ 1:5;2ð Þ
there is still a substantial increase in power for the p-value weight (A,
green), the standardized test statistic (B, purple), and the CDF
transformation (C, orange) with AUC values of 90 or greater; see
Supplemental Figures S4 and S5.
3.2. Simulation II: KEGG based pathways
The second simulation makes use of the data structure of the
KEGG pathways between genes and metabolites to deﬁne the
pathways. This introduces overlapping pathways and pathways of
varying sizes into the simulation. Rather than drawing the data from a
multivariate normal distribution we use bootstrap resampling of
published gene expression data [31] to populate our vector of per-
gene test statistics. We speciﬁcally focus on those metabolites
measured in Sreekumar et al. (2009) [4] and the genes measured in
Varambally et al. (2005) [31]; 98 pathways include measurements for
both genes and metabolites.
Per-metabolite p-values are drawn fromauniform(0,1) distribution,
excluding 15 metabolites (10.2% of 147) that are selected to be
differential and have p-values drawn from a beta(3,37) distribution.
Thesemetaboliteswere selected in such away that they aremembers of
between one and ﬁve pathways with up to two of the pathways being
enriched (see Table 2). By examiningmetabolites in multiple pathways
we can assess the effect of weight summaries across pathways. By
examining metabolites that are not in enriched pathways we can
examine potential power loss due to down-weighting. The gene-set
enrichment tests, weight functions, and per-metabolite weights are
Fig. 2. True positive rates for each of the ﬁfteen differential metabolites. The metabolites are noted on the vertical axis by the number of enriched pathways with which each is
associated. The weight functions are color coded as before ((A), ωk=− log10(p), green; (B), ωk ¼ ~S
 , purple; (C), ωk ¼ Φ ~S−~μ
 
, orange; and (D), ωk ¼ exp ~S ~μ
 
, red) with the
median summary denoted by circles and the 75th percentile summary noted by triangles. The unweighted result is noted by black squares.
270 L.M. Poisson et al. / Genomics 99 (2012) 265–274calculated for each of 1000 generated gene expression datasets and
metabolite p-value vectors.
Fig. 2 shows the frequency of signiﬁcant p-values (at α=0.05) for
each of the 15 differential metabolites across the 1000 simulated data
setswhere 20% (π=0.2) of the genes in an enriched pathway are drawn
as differential; see Supplemental Figure S6 for π=0.5. The color scheme
is retained from the ﬁrst simulation (see Section 3.1). Additionally we
denote themedian summary weights by circles and the 75th percentile
weights by triangles. Notice that these weights are similar but not exact
for the four metabolites in a single pathway. Even though their per-
metabolite measures vmj=ωkj, for metabolite m, in pathway k with
weight option j, will be identical the ﬁnal weights,wmj,are standardized
against v⋅j whichwill vary depending on the other vm′j values (m′≠m),
see Section 2.2.1. The black squares represent the unweighted test
p-value and, as expected by the Beta(3,37) distribution used in
simulation, they are signiﬁcant in about 30% of the datasets.
We see in Fig. 2 that, for a given metabolite, the improvement in
power is related to the proportion of enriched pathways associated
with themetabolite. Speciﬁcally, the greater the proportion of enriched
pathways the more likely the weighting will have a positive effect. This
is due to our choice of the median and 75th percentile as a summary
measures for the per-metabolite weight contribution when there aremultiple pathways associatedwith themetabolite. Of the two summary
measures considered, the 75th percentile (triangles) tends to perform
better than the median (circles). A lower proportion of enriched
pathways is required to achieve up-weighting with the 75th percentile
than with the median. However, there are cases where the 75th
percentile is not more powerful, such as for the two metabolites with
only one enriched metabolite (i.e. 1/1). Although the median and 75th
percentiles are the same for this single value, these per-metabolite
weights must be standardized so that w ¼ 1 and thus the resulting
weights are dependent on the size of the other per-metabolite weights
in the data.
Finally, it is interesting to note that the amount of down-weighting
for the metabolites with a low proportion of enriched associated
pathways is less for the self-contained enrichment tests (i.e. binomial
and SST) than for the competitive tests (i.e.hypergeometric and KS-
test). The extent of up-weighting also appears higher for the
dichotomized test methods (i.e., binomial and hypergeometric). These
patterns persist when the strength of the pathway enrichment is
increased (e.g. π=0.5; see Figure S6).
Yet, power increases cannot be described without considering the
rate of false positive ﬁndings. The 132metabolites thatwere not chosen
to be differential can be used to determine false positive rates by
Fig. 3. Boxplots of per-metabolite false positive rates. Each method is represented by a boxplot and each data point represents a null metabolite. For instance, the exponential
weights (D) tend to have low error rates overall, but a handful of metabolites are called signiﬁcant over 400 times. The weight functions are color coded as before with the median
summary in the left box and the 75th percentile summary in the right box.
271L.M. Poisson et al. / Genomics 99 (2012) 265–274considering the percentage of signiﬁcant calls per metabolite across the
1000 simulated data sets. In Fig. 3 these percentages are plotted as
boxplots per weight function. The nominal 5% error rate is noted with a
black horizontal line. For most weight methods the majority of the
metabolites have error near the nominal line, i.e. the box contains 5%.
The unweighted tests (black) are tightly centered at 0.05 as expected by
the simulation design. However, the exponential function (D, red)
behaves poorly for all four enrichment tests with error rates nearing
50% for some metabolites. The negative log-p-value method (A, green)
has a higher error for the hypergeometric test than for the other
enrichment tests. The CDF function (C, orange) has low error in the self-
contained tests (binomial and sum of squared statistic) and the
standardized test statistic performs well except for the hypergeometric
test. There is no obvious difference between the median summary and
the 75th percentile summarywith respect to the error rates (see Fig. 3).
Increasing the pathway enrichment from π=0.2 to π=0.5 increases
the false positive calls in the competitive tests, but the self-contained
tests retain appropriate error control except for the exponential
function (D, red); see Figure S7.
3.3. Application to motivating data
We apply the method of p-value weighting to the motivating data
example of the Sreekumar et al. (2009) [4] metabolite data andmatched gene expression data (GEO:GSE8511). We begin by assessing
the pathway enrichment of the gene expression data. Two-sample t-
tests were used to assess the difference of gene expression between
localized prostate cancer and adjacent benign tissues, per gene. All four
enrichment methods were then applied. When required, permutation
p-values were calculated from 1000 permutations of the sample labels.
Permutation p-values are limited in precision by the number of
permutations used. Here this resulted in little discrimination of
pathways for the two self-contained tests; binomial and sumof squared
statistics. The statistic Sk, however, showed potential for discriminating
between the k pathways.
Of the twoweight functions using Sk, Simulation I lead us to favor the
CDF weighting function (C, orange) and the standardized test statistic
(B, purple). The CDF functionwasmore robust to heavy tails (see Figure
S8) but the standardized test statistic (B, purple) outperformed the CDF
weighting function (C, orange) in the second simulation for all but the
K–S test. Among these, the two self-contained enrichment statistics
appeared to bestmaintain control of downweighting and false positives.
Before selecting between the twoweighting functionswe decided to
further investigate the parameter ~μ , the presumed differential effect
under the alternative distribution, used in the CDF function. In the
simulations we had ﬁxed ~μ ¼ 2 but in the application dataset the
distribution of ~Sk across k shows that this choice may not be optimal.
The median ~Sk is near 6 for the hypergeometric, binomial and sum of
272 L.M. Poisson et al. / Genomics 99 (2012) 265–274squared test statistic methods and is near to zero only for the weighted
K–S approach. By assigning ~μ ¼ 2 we may be severely tempering the
upper range of test statistics and thereby reducing the ability of the
weights to differentiate pathway contributions. To assess thiswe looked
back at the data of Simulation II under the sum of squared test (π=0.2).
The range of the ~Sk values is less in the simulated data with median ~Sk
between 2.5 and 4.5 for the sum of squares method suggesting that
~μ ¼ 2 may not be optimal.
Using the ﬁrst 500 simulated data sets from Simulation II (π=0.2)
we assessed how varying ~μ affected the frequency of detection for each
of the 15 simulated differential metabolites; see Fig. 4. In the upper
panels we see that the detection rate for each metabolite increases at
ﬁrst and then decreases as ~μ becomes large. In contrast the error rates
shown in the bottom panels decrease overall (boxes) but a handful of
metabolites are falsely discovered at increasing rates. It is interesting to
note that when a median summary is used for combining weights for a
metabolite in multiple pathways (Fig. 4, left) the frequency of detecting
truly differential metabolites quickly decreases for a majority of the
metabolites. In contrast, if the 75th percentile is used to combine the
weights across pathways (Fig. 4, right) then the power loss is less and
the error rates do not increase as quickly.
From these results we consider assigning ~μ ¼ P75 Sð Þ, i.e., the 75th
percentile of the ~Sk values across all k. To test this adaptive ~μ ¼ P75 ~S
 
we analyzed the remaining 500 Simulation II datasets. We used the
sum of squares statistic and the CDF weighting function with either
~μ ¼ 2 or ~μ ¼ P75 ~S k
 
across all k. The 75th percentile statistic was used
to summarize the pathwayweight components (ωk) when ametaboliteFig. 4. Adaptive estimation of μ.̃ The effect of differing μ̃ from 1 to 15 is shown on power to d
the Type I error in the remaining 132 metabolites (one point per metabolite, bottom panels)
ﬁfth percentile (right panels) summaries are considered.was represented in multiple pathways. The ﬁxed estimate of ~μ ¼ 2
shows more consistent, though marginal, increases in detection rates
among the ﬁfteen differential metabolites; see Table 3. The adaptive
estimate of ~μ ¼ P75 ~S
 
shows stronger gains but they are balanced by
slightly stronger losses. Error rates are near to the nominal 0.05 rate,
however, the adaptive estimate gives a wider spread of errors with one
metabolite being falsely detected in up to 11.8% of the datasets.
The detection rates for the adaptive μ version of the CDF function
are over 70% for several metabolites which is better than we saw for
any of the other weight functions; see Fig. 2. For the analysis of the
Sreekumar et al. (2009) [4] metabolite data we accept the potential
losses of the adaptive method in favor of the potential for strong
gains. Thus we choose to use the sum of squares enrichment test for
gene expression with the CDF weight function, and ~μ ¼ P75 ~S
 
.
Additionally we use the seventy-ﬁfth percentile summary for
metabolites that participate in multiple pathways (Table 4).
Twenty-ﬁve metabolites were found to be signiﬁcant at pb0.05 by
both the weighted and unweighted p-values. There was a loss of eight
metabolites by the weighted method; homocysteine, asparagine,
bradykinin, cysteine, leucine, malate, N-acetylaspartate, and oxalate.
However, there was a gain of ten metabolites resulting in a net gain of
two metabolites; N-acetylneuraminate, adenine, argininosuccinate,
aspartate, glycerol, guanosine, hypoxanthine, orotidine-5′-phosphate,
spermine and xanthosine. In the original publication [4] leucine was
listed as a metabolite up-regulated from benign to metastatic disease
so this loss is notable. Additionally there was an enrichment of amino
acids detected in the differential metabolites originally and some areetect each of the 15 differential metabolites (one curve per metabolite, top panels) and
. For metabolites involved in multiple pathways, both median (left panels) and seventy-
Table 4
Comparing estimators of μ̃. Using 500 simulated datasets from Simulation II (π=0.2),
we calculate the percentage of times the metabolites are detected to be differential. The
ﬁfteen differential metabolites are listed by the proportion of enriched pathways in
which each is included. An adaptive and a ﬁxed estimation of μ̃ are compared to the
unweighted results. Median and maximum Type I error rates for the 132 non-
differential metabolites are given in the bottom rows.
Proportion enriched ~μ ¼ P75 ~μ ¼ 2 Unwt.
2/5 0.656 0.484 0.320
1/5 0.408 0.398 0.350
0/5 0.276 0.308 0.298
1/4 0.536 0.480 0.340
0/4 0.414 0.384 0.308
2/3 0.700 0.476 0.310
1/3 0.518 0.366 0.284
0/3 0.344 0.416 0.320
2/2 0.706 0.484 0.328
1/2 0.726 0.484 0.294
0/2 0.368 0.412 0.320
1/1 0.512 0.382 0.252
1/1 0.496 0.404 0.324
0/1 0.192 0.240 0.308
0/1 0.160 0.162 0.280
Median error 0.044 0.050 0.048
Max error 0.118 0.078 0.076
273L.M. Poisson et al. / Genomics 99 (2012) 265–274lost with the weighted analysis (e.g. leucine, cysteine) but aspartate is
gained. Finally, sarcosine, which was of primary interest originally,
had a decreased p-value in the weighted analysis (0.029 unweighted;
0.016 weighted) suggesting that this ﬁnding is supported by gene-set
enrichment results.
Interestingly, we now signiﬁcantly detect a decrease of spermine
in tumor cells, which has been shown elsewhere to be decreased in
prostate cancer tissues and spermine dysregulation was shown to be
associated with increased probability of biochemical recurrence [32].
Additionally, we have detected the purine and purine sugars adenine,
guanosine, xanthosine, and hypoxanthine. Along with adenosine,
which was detected originally, these all react with the enzyme
purine-nucleoside phosphorylase, an enzyme with oncogenic effects
when dysregulated [33]. Further, metabolites of purine nucleoside
phosphorylase have been found to be potential serum biomarkers in
pancreatic cancer [34]. Thus the use of gene expression weighting has
drawn attention to new metabolite concepts that were missed when
the two data types were analyzed separately.4. Discussion
Here we have explored the utility of gene-based p-value weight-
ing to enhance the power to detect differential metabolites. Genes
and metabolites were related via a priori deﬁned pathways. Gene set
enrichment scores were used to summarize the gene expression data
by these pathways. Four enrichment tests of varying style and four
weight functions were considered for constructing the per-
metabolite weights.
The weight function converts the gene set enrichment information
(p-value or test statistic) into a non-negative weight that increases
with increasing importance. We chose to explore the CDF (C, orange)
and exponential (D, red) weight functions suggested by Roeder et al.
(2006) [24], as they present both bounded (C) and unbounded (D)
options for weight construction. As expected, the CDF function (C,
orange) is better suited to the integration of gene expression and
metabolite data by pathways than the exponential function (E, red)
which is better suited for strong and sparse regions of upregulation.
This is particularly obvious in the second simulation (see Fig. 2).
Notice that the exponential function (red) shows the potential for
great improvement in detection of metabolites with a highproportion of enriched pathway associations, but those metabolites
not associated with a sufﬁcient number of enriched pathways were
severely down-weighted and rarely detected. Additionally the strong
up-weights of metabolites in enriched pathways falsely identiﬁed
many metabolites that were associated with differential-gene
enriched pathways but not simulated to be differential (see Fig. 3).
The strength of the exponential weight is also ampliﬁed by the choice
~μ which was set at ~μ ¼ 2. When we reduce the parameter to ~μ ¼ 1 we
see that the exponential weight method (D, red) is improved (e.g.
AUC=0.61 to 0.71) but not to the level of the CDF transformation
weights (C, orange, e.g. AUC=0.96); see Figure S9.
In contrast, the CDF function (orange) showed a more moderate
improvement in detection without the severe down-weighting (see
Fig. 2). When we allow the parameter mu to be selected adaptively
we see even stronger gains in detection, albeit with slightly
stronger down-weighting (see Section 3.3). The standardized
enrichment test statistic (C, purple) also performed well in
simulation and was among the best performers of the second
simulation. However, the CDF function of the standardized test
statistic is more robust when the tails of the per-gene test statistics
are long (see Figure S8).
The p-value weight (A, green) performed well in Simulation I but
had mixed results in the more complex second simulation. The high
detection rates with the hypergeometric test (Fig. 2, top left) were
met with higher error rates (Fig. 3, top left). Additionally, like the
exponential function, these higher detection rates imposed stronger
down-weights. For the other three tests the performance is more
moderate. Interestingly, these three tests used a permutation p-value
which was bounded at 1/1000 due to the number of permutations
used. In contrast, the hypergeometric test used an exact p-value
which has greater range, given the sample size, leading to the larger
range of weights.
Considering both simulations we recommend using the CDF
function (ωk ¼ Φ ~S−~μ
 
, with ~S ¼ S−E S0ð Þð Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var S0ð Þ
p
), especially
when the distribution of the per-gene test statistics has long tails.
Alternatively, a thresholded enrichment test can be used which
ignores the magnitude of the per-gene test statistics by classifying
each test as differential or not. In application we discovered that the
use of ~μ ¼ 2 may not be optimal and an adaptive method for
estimating ~μ was explored. This adaptive method not only produced
more consistent gains for some differential metabolites but also
resulted in more severe losses. The choice of a ﬁxed or adaptive ~μ
should be made in consideration of the study goals. When a
continuous enrichment test is desired, we prefer the self-contained
sum of squared statistic test to the weighted Kolmogorov–Smirnov
(K–S) test since the self-contained tests appear to maintain control on
the false positives and resist heavy down-weighting.
Another appealing feature of the p-value weighting method is that
all metabolites can be considered in the analysis. Currently, as few as
one third of the metabolites measured are identiﬁed [4]. As mass
spectrometry libraries are expanded this number will increase but
until then those metabolites that are unknown or are not mapped to
gene expression are simply awarded a weight of 1. This does not
adjust the p-value nor does it affect the requirement that the weights
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